Core Viewpoint - GENFIT is actively participating in the EASL Annual Congress 2025, showcasing its commitment to advancing research in Acute-on-Chronic Liver Failure (ACLF) through six poster presentations and various events aimed at enhancing awareness and collaboration within the hepatology community [1][24]. Posters - Six posters accepted for presentation at the EASL Congress focus on GENFIT's assets related to ACLF, including real-world data research [2]. - Poster 1 discusses the investigational drug VS-01 and its effects on metabolite accumulation in patients with acutely decompensated liver cirrhosis [3]. - Poster 2 presents findings on the efficacy of the ASK1 inhibitor SRT-015 in disease models [4]. - Poster 3 highlights CLM-022 as a potential treatment for inflammatory liver diseases [4]. - Poster 4 examines NTZ's role in alleviating hepatocyte cell death in ACLF models [5]. - Poster 5 utilizes a machine-learning algorithm to identify at-risk subpopulations in ACLF patients [6]. - Poster 6 focuses on the development of models for detecting MASH resolution and fibrosis improvement [7]. Events - GENFIT will participate in an EASL Studio session discussing ACLF, moderated by Professor Debbie Shawcross, with industry representatives including GENFIT and Boehringer Ingelheim [8]. - A co-hosted event with EF CLIF on May 7, 2025, will explore scientific insights and updates on GENFIT's ACLF pipeline [10]. - A KOL ACLF Advisory Board meeting will facilitate discussions on collaboration opportunities and data-driven decision-making [11]. - An UNVEIL-IT® study meeting will take place on May 8, 2025, involving key opinion leaders and investigators in ACLF [13]. - A new ACLF Patient Advocacy Council session will focus on awareness and regulatory engagement from a patient perspective [14]. - GENFIT will engage in a roundtable discussion on the use of AI tools in hepatology drug development [15]. About ACLF - ACLF is characterized by hepatic and extrahepatic organ dysfunctions, with a high short-term mortality rate ranging from 23% to 74% within 28 days [18]. - The prevalence of ACLF was estimated at approximately 294,000 in the US, EU4, and UK in 2021, projected to reach around 300,000 by 2036 [18]. - The incidence of ACLF has been increasing at an epidemic rate, with a 26% rise between 2006 and 2014, attributed to factors such as an aging population and higher prevalence of liver diseases [18]. About GENFIT - GENFIT is a late-stage biopharmaceutical company focused on rare, life-threatening liver diseases, with a diverse R&D portfolio targeting ACLF [19]. - The company has five assets under development for ACLF, including VS-01, G1090N, SRT-015, CLM-022, and VS-02-HE, utilizing various mechanisms of action [19]. - GENFIT has a history of successful drug development, including the accelerated approval of elafibranor for Primary Biliary Cholangitis [21].
GENFIT to Present Latest ACLF Research at EASL Congress 2025